Back

Characterisation of triglyceride changes and cardiotoxicity during fluoropyrimidine therapy

20 June 2026 (10:45 - 11:45)
Organised by: Logo
Congress Presentation Part of: Clinical science in cardio-oncology Stratification, Prevention and Monitoring Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor James Morris Wilson

Barts Heart Centre, London (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Streamlining event ascertainment in cancer randomised controlled trials: accuracy of the SCORE-CVD-MI algorithm using health system data in a large prostate cancer trial
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides
Presentation thumbnail
Interrogating mechanisms of fluoropyrimidine cardiotoxicity: a prospective stress CMR study
Doctor A. Abiodun (London, GB)
Abstract Slides
Presentation thumbnail
Personalised and unified longitudinal surveillance in cardio-oncology (PULSO): design of a digitally enabled multidisciplinary observational study.
Mrs C. Contreras (Madrid, ES)
Abstract Slides
Presentation thumbnail
Deep-learning analysis of 12-lead ECGs detects drug-induced hERG inhibition and improves risk stratification beyond QTc
Doctor M. Liang (US)
Abstract Slides
Presentation thumbnail
Cardiovascular disease in breast cancer patients receiving chemotherapy: epidemiology and risk factors
Doctor V. Dvorovy (Bratislava, SK)
Abstract Slides

Access the full session

Session thumbnail
Clinical science in cardio-oncology

The Event

Event poster

ESC Cardio-Oncology 2026

20 June 2026 10:45 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources